Informed consent for HIV cure research in South Africa: issues to consider

BMC Medical Ethics

Ciara Staunton¹ 

[1] Centre for Medical Ethics and Law, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 19063, Francie van Zijl Drive, 7505 Tygerberg, South Africa

关键词: Therapeutic misconception;    Informed consent;    HIV/AIDS cure;    HIV/AIDS;   

Others  :  1089916
DOI  :  10.1186/1472-6939-16-3

 received in 2014-08-11, accepted in 2015-01-02,  发布年份 2015

【 摘 要 】

Background

South Africa has made great progress in the development of HIV/AIDS testing, treatment and prevention campaigns. Yet, it is clear that prevention and treatment campaigns alone are not enough to bring this epidemic under control.

Discussion

News that the “Berlin patient” and the “Mississippi baby” have both been “cured” of HIV brought hope to people living with HIV/AIDS in South Africa that a cure for HIV/AIDS is within reach. Despite the recent setbacks announced in the “Mississippi Baby” case, protocols aimed at curing HIV/AIDS are being developed in South Africa. However with evidence to suggest that participants in clinical trials do not understand the basic concepts in the informed consent process, there is concern that future participants in HIV/AIDS cure research will lack comprehension of the basic elements of future clinical trials that aims to cure HIV/AIDS and confuse research with clinical care.

Summary

Research ethics committees have an important role to play in ensuring that participants understand the basic concepts discussed in the informed consent process, that they understand that research is not clinical care and they are unlikely to benefit from any early phase trials seeking to cure HIV/AIDS.

【 授权许可】

   
2015 Staunton; licensee BioMed Central.

【 参考文献 】

• [1]Watson J: Scientists, activists sue South Africa’s AIDS ’denialists’. Nat Med 2006, 12:6.
• [2]Fassin D, Schneider H: The politics of AIDS in South Africa: Beyond the Controversies. BMJ 2003; 326: 495–497. J. Watson. Scientists, activists sue South Africa’s AIDS ’denialists’. BMJ 2003, 326:495-7.
• [3]Diethelm P, McKee M: Denialism: what is it and how should scientists respond? Eur J Public Health 2009, 19:2-4.
• [4]Council SANA: The National HIV Counselling and Testing Campaign Strategy. 2010.
• [5]Simbayi LC, Shisana O, Rehle T, Onoya D, Jooste S, Zungu N, Labadarios D, Zuma K: South African National HIV Survey 2012. 2014.
• [6]Organisation WH: Global Update on HIV Treatment 2013: Results, Impacts and Opportunities. 2013.
• [7]Mbengashe ZN T, Chipimo M, Chidarikire T, Diseko L: The National HIV Counselling and Testing Campaign and Treatment Expansion in South Africa: A Return on Investments in Combination Prevention. 19th International AIDS Conference. July 22-27, Washington DC, Poster Abstract THPDE0304 2003.
• [8]Rehle T, Hallett T, Shisana O, Wyk VP-v, Zuma K, Carrara H, Jooste S: A decline in new HIV infections in South Africa: estimating HIV incidence from three National HIV surveys in 2002, 2005 and 2008. PLoS 2010, 5:e11094.
• [9]Bor J, Herbst A, Newell M, Barnighausen T: Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013, 339:961-5.
• [10]Johnson L, Mossong J, Dorrington R, Schomaker M, Hoffmann C, Keiser O, Fox M, Wood R, Prozesky J, Giddy J, et al.: Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 2013, 10:e1001418.
• [11]How South Africa’s fight against HIV stacks up”. [http://www.health-e.org.za/2013/09/23/south-africas-fight-hiv-stacks/ webcite]
• [12]Katz I, Bassett I, Wright A: PEPFAR in transition — implications for HIV care in South Africa. New Eng J Med 2013, 369:1385-7.
• [13]Hütter G, Nowak D, Mossner M, Ganepola S, Müßig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, et al.: Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. New Eng J Med 2009, 360:692-8.
• [14]Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun T, Strain M, Richman D, Luzuriaga K: Absence of detectable HIV-1 viremia after treatment cessation in an infant. New Eng J Med 2013, 369:1828-35.
• [15]Tucker J, Rennie S: Social and ethical implications of HIV cure research. AIDS 2014, 28(9):1247-50.
• [16]Tucker J, Volberding P, Margolis D, Rennie S, Barre-Sinoussi F: Words matter: discussing research towards an HIV cure in research and clinical contexts’. J Aquir Immune Defic Syndr 2014, 67(3):e110-1.
• [17]McNeil D: Early Treatment Found to Clear H.I.V. in 2nd Baby. New York Times 2014.
• [18]Cohen J: HIV resurfaces in 'Mississippi baby' many presumed cured Science . [http://news.sciencemag.org/biology/2014/07/hiv-resurfaces-mississippi-baby-many-presumed-cured webcite]
• [19]Hayden EC: Nature. 2014.
• [20]Cure TIASSWGoH: Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012, 12:607-14.
• [21]Group TSfMoATSS: CD4+ count–guided interruption of antiretroviral treatment. New Eng J Med 2006, 355:2283-96.
• [22]Karim Q, Karim S, Coovadia H, Susser M: Informed consent for HIV testing in a South Africa Hospital: is it truly informed and truly voluntary? Am J Public Health 1998, 88:637-40.
• [23]Joubert G, Steinberg H, Ryst E, Chikobvu P: Consent for participation in the Bloemfontein Vitamin A trial: how informed and voluntary? Am J Public Health 2003, 93:582-4.
• [24]Moodley K, Pather M, Myer L: Informed consent and participant perceptions of influenza vaccine trials in South Africa. J Med Ethics 2005, 31:727-32.
• [25]Groves A, Maman S, Msomi N, Makhanya D, Moodley D: The complexity of consent: women’s experiences testing for HIV at an antenatal clinic in Durban. AIDS Care 2010, 2010(22):538-44.
• [26]Emanuel E, Wendler D, Grady C: What makes clinical research ethical? JAMA 2000, 283:2701-11.
• [27]Karim Q: A model designed to enhance informed consent: experiences for the HIV prevention trials network. Am J Public Health 2005, 95:412-9.
• [28]Do H: Ethics in Health Research: Principles, Structures and Processes. 2004.
• [29]Health Do: Guidelines for Good Practice in the Conduct of Clinical Trials with Human Participants in South Africa. 2006.
• [30]Council MR: HIV Preventive Vaccine Research. 2004.
• [31]UNAIDS: Ethical Considerations in Biomedical HIV Prevention Trials. 2007.
• [32]O’Neill O: Some limits of informed consent. J Med Ethics 2003, 29:4-7.
• [33]Lindegger G, Richter L: HIV vaccine trials: critical issues in informed consent. S Afr J Sci 2000, 96:313-7.
• [34]Terblanche M, Burgess L: Examining the readability of patient-informed consent forms. Open Access J Clin Trials 2010, 2:157-62.
• [35]Essack Z, Koen J, Barsdorf N, Slack C, Quayle M, Milford C, Lindegger G, Ranchod C, Mukuka R: Stakeholder perspectives on ethical challenges in HIV vaccine trials in South Africa. Dev World Bioeth 2010, 10:11-21.
• [36]Malan T, Moodley K: Phase 3 Oncology Clinical Trials in South Africa: Experimentation or Therapeutic Misconception?.
• [37]Forum WE: The Global Competitiveness Report. 2013.
• [38]Africa SS: General Household Survey 2012. 2013.
• [39]Angell M: The ethics of clinical research in the third world. New Eng J Med 1997, 337(12):847-9.
• [40]Pentz RMW, Harvey R, Luke Farmer Z, Liu Y, Lewis C, Dashevskaya O, Owonikoko T, Khuri F: Therapeutic misconception, misestimation and optimism in subjects enrolled in phase i trials. Cancer 2012, 118(18):4571-8.
• [41]Henderson G, Easter M, Zimmer C, King N, Davis A, Rothschild BB, Churchill L, Wilfond B, Nelson D: Therapeutic misconception in early phase gene transfer trials. Soc Sci Med 2006, 62:239-53.
• [42]Catt S, Langridge C, Fallowfield L, Talbot DC, Jenkins V: Reasons given by patients for participating, or not, in Phase 1 cancer trials. Eur J Cancer 2011, 47:1490-7.
• [43]Applebaum P, Roth L, Lidz C: The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatr 1982, 5:319-29.
• [44]Horng S, Grady C: Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation and therapeutic optimism. IRB: Ethics Human Res 1997, 35:11-6.
• [45]Lo B, Grady C: Ethical considerations in HIV cure research: points to consider. Curr Opin AIDS 2013, 8(3):243-9.
• [46]Shapiro H: HIV ‘Cure’ Likely to be Temporary, Says Leading Scientist Robert Siliciano, Seattle Weekly News. 2014.
• [47]Amon JJ: Dangerous medicines: unproven AIDS cures and counterfeit antiretroviral drugs. Globalisation and Health 2008, 4:5. BioMed Central Full Text
• [48]Moodley K: Pluralistic Perspectives on Cure in Africa: How will Research Participants Interpret the C Word?.
• [49]Murphy DA, Hoffman D, Seage GR, Belzer M, Xu J, Durako SJ, Geiger M: The Adolescent Trials Network for HIV/AIDS Interventions. Improving comprehension for HIV vaccine trial information among adolescents at risk of HIV. Psychol Soc Med Aspects of AIDS/HIV 2007, 19:42-51.
• [50]Coletti A, Heagerty P, Sheon AR, Gross M, Koblin BA, Metzger DS, Seage GR: Randomized, controlled evaluation of a prototype informed consent process for domestic HIV vaccine trials. Psychol Soc Med Aspects of AIDS/HIV 2003, 19:42-51.
• [51]Sugarman J: HIV cure research: expanding the ethical considerations. Ann Intern Med 2013, .:.. doi: 10.7326/0003-4819-159-7-201310010-00694
• [52]Loon K, Lindegger G: Informed consent in clinical trials: perceptions and experiences of a sample of South African researchers. Health SA Gesondheid 2009, 14(1):.. doi: 10.4102/hsag.v14i1.463
• [53]Woodsong C, Karim Q: A model designed to enhance informed consent: experiences for the HIV prevention trials network. Am J Public Health 2005, 95:412-9.
• [54]Gikonyo PB C, Marsh V, Molyneux S: Taking social relationships seriously: lessons learned from the informed consent practices of a vaccine trial on the Kenyan coast. Soc Sci Med 2008, 67:708-20.
• [55]Lindegger G, Milford C, Slack C, Quayle M, Xaba X, Vardas E: Beyond the checklist: assessing understanding for HIV vaccine trial participation in South Africa. J Aquir Immune Defic Syndr 2006, 43:560-6.
• [56]Mariner WK: Taking informed consent seriously in global HIV vaccine research. J Aquir Immune Defic Syndr 2003, 32:117-23.